CLL

As I visit the cancer center for chemotherapy to treat my CLL, I can’t help but take note of how different cancer may look in each person.

During chemotherapy for my chronic lymphocytic leukemia, I try my best to appreciate the positive aspects of life, like flowers and friends.

During my chemotherapy treatments for chronic lymphocytic leukemia, I had a supportive group of people surrounding me.

It was beneficial for both myself and my loved ones when I gave a concrete answer to the question of “how can I help?”

A novel Calquence regimen demonstrated improved outcomes in certain patients with chronic lymphocytic leukemia.

More frequent immunoglobulin G testing was associated with a decreased risk of severe infections in patients with CLL and non-Hodgkin lymphoma.

Being in nature calms me, and I realized that research backs up what I’ve been experiencing.

My oncologist said that having a supportive community during cancer is just as important as treatment and I could not agree more — it makes me thankful.

Patients with chronic lymphocytic leukemia had better survival when treated with Calquence during earlier lines of therapy.

Josie Montegaard, MSN, AGPCNP-BC, and Yuliya Linhares, MD, conclude their discussion with advice for patients with CLL on managing their diagnosis and treatment.

Yuliya Linhares, MD, discusses how healthy lifestyle choices, such as diet and exercise, can play a valuable role in optimizing CLL treatment outcomes.

Patients with chronic lymphocytic leukemia or small lymphocytic lymphoma tended to be more likely to stay on treatment and experience fewer heart toxicities with Calquence or Brukinsa.

Clinical insights on shared decision-making practices and the importance of supportive care when treating patients with chronic lymphocytic leukemia.

A medical oncologist provides a comprehensive overview of treatment options for patients with relapsed/refractory chronic lymphocytic leukemia, including BTK inhibitors and CAR T-cell therapy.

An expert on chronic lymphocytic leukemia discusses adverse effects encountered by patients who are receiving BTK inhibitors or venetoclax-based regimens.

Josie Montegaard, MSN, AGPCNP-BC, provides clinical insights on her approach to counseling patients who are receiving treatment for chronic lymphocytic leukemia.

Dr Linhares discusses newer combination therapies for the treatment of patients with chronic lymphocytic leukemia, highlighting ibrutinib and venetoclax, which is being studied in the CAPTIVATE trial.

Turning the focus to ibrutinib-based therapy, Yuliya Linhares, MD, gives an overview of the RESONATE study.

Intimacy was always important in my relationship with my husband, and it continued to be even after my small lymphocytic lymphoma diagnosis.

Expert perspectives on the SEQUOIA study, which is investigating zanubrutinib in patients with chronic lymphocytic leukemia.

Yuliya Linhares, MD, discusses the CLL14 study, which is looking at venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia.

Focusing on acalabrutinib-based treatment, Yuliya Linhares, MD, discusses results from the ELEVATE TN clinical trial.

A general overview of efficacy and safety data for current treatment options for patients with chronic lymphocytic leukemia.

Josie Montegaard, MSN, AGPCNP-BC, offers expert perspectives on treatment considerations in CLL, focusing on BTK inhibitors and venetoclax-based therapy.

Dr Linhares provides clinical insights on factors that guide treatment decisions for patients with chronic lymphocytic leukemia, such as comorbidities and disease biology.

Finding out that some family members have the BRCA gene makes me worried for them regarding the prospect of cancer.

After reading a book about how Imbruvica was revolutionized for SLL and CLL, I now have a greater appreciation for the drugs I receive.

Dr Linhares gives a comprehensive overview of tests a patient might expect to undergo at the time of diagnosis and why they are important.

Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, introduce themselves and give an overview of chronic lymphocytic leukemia (CLL), highlighting symptoms and patient presentation.

Breyanzi has been approved by the FDA for some previously treated patients with CLL or SLL — marking the first CAR-T cell therapy approved for this patient population.